A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Chicago
Celgene
Peter MacCallum Cancer Centre, Australia
Merck Sharp & Dohme LLC
Washington University School of Medicine
Mayo Clinic
University Health Network, Toronto
NYU Langone Health
Yale University
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
University of Cologne
Ohio State University Comprehensive Cancer Center
Washington University School of Medicine
GiovanniPascale
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center